These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 7865282)

  • 1. Immunogenicity and HIV-1 virus neutralization of MN recombinant glycoprotein 120/HIV-1 QS21 vaccine in baboons .
    Powell MF; Cleland JL; Eastman DJ; Lim A; Murthy K; Newman MJ; Nunberg JH; Weissburg RP; Vennari JC; Wrin T
    AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S105-8. PubMed ID: 7865282
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of a single-shot subunit vaccine for HIV-1.
    Cleland JL; Powell MF; Lim A; Barrón L; Berman PW; Eastman DJ; Nunberg JH; Wrin T; Vennari JC
    AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S21-6. PubMed ID: 7865303
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HIV-1MN recombinant glycoprotein 160 vaccine-induced cellular and humoral immunity boosted by HIV-1MN recombinant glycoprotein 120 vaccine. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group.
    Gorse GJ; Corey L; Patel GB; Mandava M; Hsieh RH; Matthews TJ; Walker MC; McElrath MJ; Berman PW; Eibl MM; Belshe RB
    AIDS Res Hum Retroviruses; 1999 Jan; 15(2):115-32. PubMed ID: 10029244
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of dose and immunization schedule on immune response of baboons to recombinant glycoprotein 120 of HIV-1.
    Anderson KP; Lucas C; Hanson CV; Londe HF; Izu A; Gregory T; Ammann A; Berman PW; Eichberg JW
    J Infect Dis; 1989 Dec; 160(6):960-9. PubMed ID: 2555423
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of adjuvants on immunogenicity of MN recombinant glycoprotein 120 in guinea pigs.
    Powell MF; Eastman DJ; Lim A; Lucas C; Peterson M; Vennari J; Weissburg RP; Wrin T; Kensil CR; Newman MJ
    AIDS Res Hum Retroviruses; 1995 Feb; 11(2):203-9. PubMed ID: 7742035
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of a single-shot subunit vaccine for HIV-1. 5. programmable in vivo autoboost and long lasting neutralizing response.
    Cleland JL; Lim A; Daugherty A; Barron L; Desjardin N; Duenas ET; Eastman DJ; Vennari JC; Wrin T; Berman P; Murthy KK; Powell MF
    J Pharm Sci; 1998 Dec; 87(12):1489-95. PubMed ID: 10189254
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neutralizing antibodies to HIV-1 in seronegative volunteers immunized with recombinant gp120 from the MN strain of HIV-1. NIAID AIDS Vaccine Clinical Trials Network.
    Belshe RB; Graham BS; Keefer MC; Gorse GJ; Wright P; Dolin R; Matthews T; Weinhold K; Bolognesi DP; Sposto R
    JAMA; 1994 Aug; 272(6):475-80. PubMed ID: 7913731
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibody to native human immunodeficiency virus type 1 envelope glycoproteins induced by IIIB and MN recombinant gp120 vaccines. The NIAID AIDS Vaccine Evaluation Group.
    Gorse GJ; Patel GB; Newman FK; Belshe RB; Berman PW; Gregory TJ; Matthews TJ
    Clin Diagn Lab Immunol; 1996 Jul; 3(4):378-86. PubMed ID: 8807200
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of a single-shot subunit vaccine for HIV-1. 3. Effect of adjuvant and immunization schedule on the duration of the humoral immune response to recombinant MN gp120.
    Cleland JL; Barrón L; Daugherty A; Eastman D; Kensil C; Lim A; Weissburg RP; Wrin T; Vennari J; Powell MF
    J Pharm Sci; 1996 Dec; 85(12):1350-7. PubMed ID: 8961152
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune response in rhesus macaques after mixed modality immunisations with DNA, recombinant adenovirus and recombinant gp120 from human immunodeficiency virus type 1.
    Vinner L; Therrien D; Wee E; Laursen I; Hanke T; Corbet SL; Fomsgaard A
    APMIS; 2006 Oct; 114(10):690-9. PubMed ID: 17004972
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of cross-reactive cytotoxic T-lymphocyte responses specific for HIV-1 gp120 using saponin adjuvant (QS-21) supplemented subunit vaccine formulations.
    Newman MJ; Wu JY; Gardner BH; Anderson CA; Kensil CR; Recchia J; Coughlin RT; Powell MF
    Vaccine; 1997 Jun; 15(9):1001-7. PubMed ID: 9261947
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Native but not denatured recombinant human immunodeficiency virus type 1 gp120 generates broad-spectrum neutralizing antibodies in baboons.
    Haigwood NL; Nara PL; Brooks E; Van Nest GA; Ott G; Higgins KW; Dunlop N; Scandella CJ; Eichberg JW; Steimer KS
    J Virol; 1992 Jan; 66(1):172-82. PubMed ID: 1727480
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Microparticles in MF59, a potent adjuvant combination for a recombinant protein vaccine against HIV-1.
    O'Hagan DT; Ugozzoli M; Barackman J; Singh M; Kazzaz J; Higgins K; Vancott TC; Ott G
    Vaccine; 2000 Mar; 18(17):1793-801. PubMed ID: 10699327
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MN and IIIB recombinant glycoprotein 120 vaccine-induced binding antibodies to native envelope glycoprotein of human immunodeficiency virus type 1 primary isolates. National Institute of Allergy and Infectious Disease Aids Vaccine Evaluation Group.
    Gorse GJ; Patel GB; Mandava M; Berman PW; Belshe RB
    AIDS Res Hum Retroviruses; 1999 Jul; 15(10):921-30. PubMed ID: 10408729
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential immune responses to HIV-1 envelope protein induced by liposomal adjuvant formulations containing monophosphoryl lipid A with or without QS21.
    Beck Z; Matyas GR; Jalah R; Rao M; Polonis VR; Alving CR
    Vaccine; 2015 Oct; 33(42):5578-5587. PubMed ID: 26372857
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and Immunogenicity of a Randomized Phase 1 Prime-Boost Trial With ALVAC-HIV (vCP205) and Oligomeric Glycoprotein 160 From HIV-1 Strains MN and LAI-2 Adjuvanted in Alum or Polyphosphazene.
    O'Connell RJ; Excler JL; Polonis VR; Ratto-Kim S; Cox J; Jagodzinski LL; Liu M; Wieczorek L; McNeil JG; El-Habib R; Michael NL; Gilliam BL; Paris R; VanCott TC; Tomaras GD; Birx DL; Robb ML; Kim JH
    J Infect Dis; 2016 Jun; 213(12):1946-54. PubMed ID: 26908741
    [TBL] [Abstract][Full Text] [Related]  

  • 17. AIDSVAX (MN) in Bangkok injecting drug users: a report on safety and immunogenicity, including macrophage-tropic virus neutralization.
    Migasena S; Suntharasamai P; Pitisuttithum P; Kitayaporn D; Wasi C; Huang W; Vanichseni S; Koompong C; Kaewkungwal J; Raktham S; Ippolito T; Hanson C; Gregory T; Heyward WL; Berman P; Francis D
    AIDS Res Hum Retroviruses; 2000 May; 16(7):655-63. PubMed ID: 10791876
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I trial in HIV negative healthy volunteers evaluating the effect of potent adjuvants on immunogenicity of a recombinant gp120W61D derived from dual tropic R5X4 HIV-1ACH320.
    McCormack S; Tilzey A; Carmichael A; Gotch F; Kepple J; Newberry A; Jones G; Lister S; Beddows S; Cheingsong R; Rees A; Babiker A; Banatvala J; Bruck C; Darbyshire J; Tyrrell D; Van Hoecke C; Weber J
    Vaccine; 2000 Jan; 18(13):1166-77. PubMed ID: 10649617
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Demographic factors that influence the neutralizing antibody response in recipients of recombinant HIV-1 gp120 vaccines.
    Montefiori DC; Metch B; McElrath MJ; Self S; Weinhold KJ; Corey L;
    J Infect Dis; 2004 Dec; 190(11):1962-9. PubMed ID: 15529261
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lessons from a multisite international trial in the Caribbean and South America of an HIV-1 Canarypox vaccine (ALVAC-HIV vCP1452) with or without boosting with MN rgp120.
    Cleghorn F; Pape JW; Schechter M; Bartholomew C; Sanchez J; Jack N; Metch BJ; Hansen M; Allen M; Cao H; Montefiori DC; Tomaras GD; Gurunathan S; Eastman DJ; do Lago RF; Jean S; Lama JR; Lawrence DN; Wright PF;
    J Acquir Immune Defic Syndr; 2007 Oct; 46(2):222-30. PubMed ID: 17693888
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.